Actualités

Pfizer Inc. (NYSE:PFE) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. A caller inquired if they should hold, sell, or buy more. In response, Cramer said: Pfizer does not have any earnings momentum. You’re just buying it on that dividend […]

Moby summary of Protalix BioTherapeutics, Inc.'s Q1 2026 earnings call

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

On Wednesday, Valneva (NASDAQ:VALN) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://edge.media-server.com/mmc/p/xbkzgkz7 Summary Valneva SE reported first-quarter revenues of approximately €30 million, with a decline from the previous

The market seemed underwhelmed by last week's earnings announcement from Pfizer Inc. ( NYSE:PFE ) despite the healthy...

Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.

Novavax (NASDAQ:NVAX) executives used the company’s first-quarter 2026 earnings call to highlight continued progress in reshaping the business around partner-driven revenue, a leaner operating model, and selective internal R&D designed to seed additional collaborations. Strategy centered on par

Moby summary of Pfizer Inc.'s Q1 2026 earnings call

Pfizer beats Q1 estimates as new launches and acquired drugs lift sales, offsetting COVID declines, while the drugmaker reaffirms its 2026 outlook.

Pfizer Inc (NYSE:PFE, XETRA:PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on Tuesday, driven by strong growth in its launched and acquired products, as the drugmaker reaffirmed its full-year financial outlook. The pharmaceutical giant posted...

All three major US stock indexes were up in late-morning trading Tuesday, as oil prices slid despite

BioNTech (NASDAQ:BNTX) executives used the company’s first-quarter 2026 earnings call to highlight a strategy centered on combination oncology therapies, provide updates on late-stage clinical programs, and outline capital allocation plans that include a $1 billion ADS share repurchase program and m

Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Revenue reached $14.45 billion, up 5% year-over-year, as oncology and other recently launched products offset steep declines in COVID products

Pfizer (PFE) delivered earnings and revenue surprises of +5.63% and +4.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

US equity futures were trending higher on Tuesday as traders await a fresh batch of corporate earnin

Pfizer shares rose slightly in premarket trading after the company delivered a first-quarter earnings beat and reaffirmed its full-year outlook. The drugmaker posted adjusted earnings of 75 cents a share, ahead of the 72 cents Wall Street had forecast. Pfizer reaffirmed its full-year guidance, which it initially provided in December.

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors should know.

Pfizer Inc. will release earnings for its third quarter before the opening bell on Tuesday, May 5. Analysts expect the pharmaceutical company to report quarterly earnings of 72 cents per share. That’s down from 92 cents per share in the year-ago period. Benzinga Pro puts the consensus estimate for Pfizer's quarterly revenue at $13.8 billion. Pfizer reported $13.71 billion last year. With the recent buzz around the company, some investors are eyeing potential gains from its dividends. Currently,